With CRISPR in Humans On the Horizon, Will the Public Back Intellia?
By Alex Lash,
Xconomy
| 04. 29. 2016
Untitled Document
Boston — An icy March wind was blowing across the Charles River, but in the laboratory of Intellia Therapeutics, the 1970s soft-rock hit “Summer Breeze” was blasting. Chief scientific officer Tom Barnes apologized. “Usually it’s heavy metal,” he said. He pointed out a window to a local tower, visible over the Cambridge, MA rooftops, rising from a nearby neighborhood. Intellia’s new offices were somewhere near there, out of our line of sight.
The two year old company’s more fateful impending move is a push to go public. Its IPO is scheduled for next week. That means the company, working to create new medicines with arguably the biggest biomedical innovation of the 21st century—the groundbreaking form of gene editing called CRISPR-Cas9—must convince investors to bet on its future even though it lacks what so many biotech investors crave: data from human clinical trials. What will CRISPR-Cas9 do when it gets into human cells and changes their DNA?
Intellia indicated in regulatory filings Wednesday it wants to raise $85 million in an IPO, plus a few million more if all...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Jennifer Denbow, Guest Contributor
| 10.29.2026
Almost every day I am reminded that we are in the midst of a fertility panic. Whether it’s the Vice President exhorting Americans to have more babies or The New York Times running yet another story about the fertility cliff, fear about falling fertility rates is everywhere. While centrally concerned with declining rates of childbearing, Anna Louie Sussman’s new book, Inconceivable: The Impossibility of Family in an Age of Uncertainty, is a welcome antidote to the panic.
Sussman has written...
By Anna Louie Sussman, The New Republic | 10.26.2026
There’s a certain kind of novel that’s not quite apocalyptic enough to be science fiction, but just far-fetched enough to be speculative. No one is from outer space; society has not yet been carved up into a hierarchy of groups...
By Gary Sernovitz, Bloomberg | 10.21.2026
Three years ago, at the age of 50, I found out I have dangerous genes. So in June, I went to Cambridge, Massachusetts, to see how they could be fixed. Among my 6 billion base pairs of DNA are two...